Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.86 |
| ▸ | NQO2 | P16083 | 1/20 | 0.72 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-38877618 SCHEMBL29391956 | 1.00 | MET (0.86) | METNQO2PDE3BPDE3APIP4K2C | |
| Jnj-38877618 SCHEMBL2492511 | 1.00 | MET (0.86) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL2697192 | 0.93 | MET (1.00) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9910502 | 0.92 | MET (0.86) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL9910501 | 0.92 | MET (0.86) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12049490 | 0.91 | MET (0.84) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL2497960 | 0.90 | MET (0.83) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12049489 | 0.88 | MET (0.80) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12049498 | 0.88 | MET (0.80) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL2496429 | 0.88 | MET (0.76) | METNQO2PDE3BPDE3APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2023077030-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021163064-A9 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | JOUNCE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4103285-A2 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | Jounce Therapeutics, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115087488-A | Antibodies and fusion proteins binding to CCR8 and uses thereof | 震动疗法股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4052040-A1 | ANTI-CD47 AND ANTI-CD20 BASED TREATMENT OF BLOOD CANCER | Forty Seven, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114867530-A | MCL1 inhibitors | 吉利德科学公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114599392-A | anti-CD 47 and anti-CD 20 based treatment of leukemia | 四十七公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114555123-A | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia | 四十七公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |